Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-1,783
Closed -$555K 8
2025
Q1
$555K Buy
1,783
+974
+120% +$288K 0.13% 90
2024
Q4
$211K Buy
809
+1
+0.1% +$297 0.05% 179
2024
Q3
$260K Sell
808
-18
-2% -$5.89K 0.06% 161
2024
Q2
$258K Buy
826
+88
+12% +$25.9K 0.06% 162
2024
Q1
$210K Buy
738
+1
+0.1% +$293 0.05% 179
2023
Q4
$212K Buy
+737
New +$201K 0.06% 172
2020
Q4
Sell
-915
Closed -$233K 284
2020
Q3
$233K Buy
915
+2
+0.2% +$495 0.07% 200
2020
Q2
$215K Buy
+913
New +$208K 0.07% 193
2019
Q2
Sell
-2,968
Closed -$564K 304
2019
Q1
$564K Buy
2,968
+576
+24% +$110K 0.16% 129
2018
Q4
$466K Buy
2,392
+851
+55% +$166K 0.18% 125
2018
Q3
$320K Buy
+1,541
New +$304K 0.11% 177

Other funds holding AMGN

Cutter & Co Brokerage's AMGN Position: Q2 2025 in Review

Cutter & Co Brokerage sold out of Amgen (AMGN) in Q2 2025, closing a stake of 1,783 shares — an estimated $555K sold.

Cutter & Co Brokerage first reported a position in AMGN in Q3 2018 and held it in 11 quarters. The position peaked at $564K in Q1 2019. 2,852 funds tracked by Wall St. Rank hold AMGN as of Q2 2025.

  • Cutter & Co Brokerage reported no remaining Amgen position as of Q2 2025 after selling out during the quarter.
  • Cutter & Co Brokerage sold 1,783 Amgen shares in Q2 2025, an estimated $555K.
  • Cutter & Co Brokerage first reported a position in Amgen in Q3 2018 and held it in 11 quarters.
  • Cutter & Co Brokerage's Amgen position peaked at $564K in Q1 2019.
  • 2,852 funds tracked by Wall St. Rank held Amgen as of Q2 2025.

Based on Cutter & Co Brokerage's 13F filing for Q2 2025.